Fred Hutchinson Cancer Research Center immunotherapy pioneer Dr. Phil Greenberg was honored last night with a Gold Award for Achievement in Medical Research at Seattle Business Magazine’s 2018 Leaders in Health Care Awards at Bell Harbor International Conference Center in Seattle. A panel of expert judges chose honorees in 10 categories based on their work to improve health care in the state.

Dr. Phil Greenberg addresses the audience at Seattle Business Magazine's Leaders in Health Care Awards March 1.

Greenberg, head of the Hutch’s Program in Immunology, is developing new methods to train patients’ T cells to be effective and precise cancer killers. His work over the decades has been foundational for the development of the field. More than 40 of his former trainees now lead their own labs around the world, and several cell products developed in his lab have shown promise against different cancers in clinical trials.

“It’s really a very remarkable thing to realize that we can actually do this [T-cell therapy] now,” Dr. Phil Greenberg said in his acceptance speech for the Gold Award for Achievement in Medical Research. “We’ve always said in the laboratory that you should shoot for the moon, because even if you miss, you wind up among the stars.”

March 2, 2018 | By Susan Keown / Fred Hutch News Service


Photo courtesy of Seattle Business Magazine



Event Details


Michael Gale Jr., Ph.D.
Professor, Department of Immunology
University of Washington

“The Center for Innate Immunity and Immune Disease”

November 30, 2015

3:30 p.m., Orin Smith Auditorium, SLU 
4:30 p.m., Reception in Orin Smith Lobby (Reception sponsored by Kineta, Inc. and the CIIID)

The Center for Innate Immunity and Immune Disease (CIIID) is new focus center to serve the UW School of Medicine and the Seattle research community. The Center serves to link multiple biomedical disciplines for research, training, and program development. Our focus within the growing field of innate immunity aims to support collaboration for the advancement and translation of basic concepts in immune regulation and immunologic disease into clinical applications for improving human health. This presentation will preview the Center’s structure, research focus, service cores, educational programs, and membership opportunities. (

The Department of Immunology gratefully acknowledges the generous contributions in support of this series from the Benaroya Research Institute and the Weiser Education Fund.

Ashraful Haque, PhD,  Associate Professor, Malaria Immunology Group Leader, QIMR Berghofer Medical Research Institute, Australia

"Using Single-Cell Genomics, mathematical and computational modelling to examine host-parasite interactions in experimental malaria"

MONDAY, March 19, 2018

850 Republican St. @ SOUTH LAKE UNION

Questions? Contact: Sarah Bland – 206.685.3956

To request disability accommodation contact the UW Disability Services Office at:  206.543.6450/V, 206.543.6452/TTY, 206.685.7264/FAX, or

Asraful Haque, PhD


Ashraful Haque, PhD

Congratulations to UW Immunology graduate students and postdocs for receiving 9 awards at this year's 57th Midwinter Conference of Immunologists at Asilomar. There are 21 awards given annually.  This year a special donation allowed an additional 15 awards. From the special donation, the Excellence Awards were sponsored by The National Philanthropic Trust.

Excellence Award Receipients: 

  • Annelise Snyder (Oberst Lab)
  • Katie Wagner (Goverman Lab)
  • Rudy Nazitto (Aderem Lab)
  • Kristen Mittelsteadt (Campbell Lab)
  • Simon Glatigny, PhD (Bettelli Lab)
  • Shivani Srivastava, PhD (Postdoc Riddell Lab)

Ray Owen Poster Award (sponsored by AAI):

  • Rebecca Olson (Aderem Lab)

Ray Owen Young Investigator Award (Oral Presentation) (sponsored by AAI):

  • Lauren Aarreberg (Gale Lab)  


It has been an excellent year for the Immunology Department and we want to share some of our news with you in our annual newsletter. We also want to thank our students, postdocs and research scientists for their talents, hard work and energy that has allowed our research to flourish, and for making this a fun place to work and learn.

Thanks also to our administrative staff for supporting everything we do, and handling the challenges of running a complex enterprise with a high degree of professionalism.

Finally, we greatly appreciate those who have donated to us this past year in support of our efforts; we have put your resources to good use. To donate this year there is a link within the newsletter or click here, your support is critical to us in helping us achieve our mission.

Department of Immunology Newsletter November 2017

The NIH Director's New Innovator Award is part of the High-Risk, High-Reward Research program, the award supports exceptionally creative early career investigators who propose innovative, high-impact projects.

Dr. Jakob von Moltke's work focuses on parasitic worms (helminths) and allergens which both induce a “type 2” immune response, however very little is known about how the immune system first senses these agonists. The Moltke lab aims to uncover how intestinal tuft cells detect helminth infection, thereby employing an entirely new and innovative entry point to understanding type 2 immune sensing. If successful, this work would establish a novel paradigm for the initiation of type 2 immune responses and could provide new targets for therapeutic intervention in helminth infection and allergy. 

Read more about the Moltke Lab project: Sensing of Helminths by Tuft Cells.


More About the NIH Director's New Innovator Award

NIH Director's New Innovator Award

The NIH Director's New Innovator Award, established in 2007, supports unusually innovative research from early career investigators who are within 10 years of their final degree or clinical residency and have not yet received a research project grant or equivalent NIH grant.

Department of Immunology announces the 2017-18 seminar series schedule. Check out the 2017–18 Immunology 573 Seminar Series Schedule

Patty Murray with Dr. Maron Pepper and Immunology Graduate Students Nicole Arroyo and Fahd al QureshahImmunology graduate students Nicole Arroyo and Fahd al Qureshah, greeted U.S. Senator Patty Murray and Dr. Marion Pepper on April 12, 2017. One by one, several UW Medicine researchers told U.S. Senator Patty Murray (D-Wash) about what cuts to the National Institutes of Health’s budget would mean for their research and their careers. Dr. William Hahn, an infectious disease fellow with the University of Washington’s School of Medicine, works with immunologist Dr. Marion Pepper. He said lack of NIH funding would mean he’d have to find another line of work. He is currently looking at why the body’s defenses don’t seem to remember contact with the malaria parasite from one exposure to the next. 

“Once we figure out the immune memory, and why the body doesn’t seem to have it with this disease, we’re on the way to making a better treatment,” he told Murray, who was in Seattle to visit the immunology labs at UW Medicine’s South Lake Union research campus. 

“You can see I have a lab of 10 people – they are the bright young stars of research – but their training and research depends on NIH grants,” Pepper told Murray after the tour. Cutting NIH funding would mean curtailing or ending new discoveries the researchers might make during their careers, Pepper added.

Read the full article on UW Health Sciences Newsbeat.

Photos: Clare McLean

Article: Barbara Clements, HSNewsBeat

A new Cell paper published by the Oberst Lab reveals breakthrough findings indicating an unexpected diversity in the outcomes of RIPK1 and RIPK3 signaling within the central nervous system not observed in other tissues. Congratulations to Brian P. Daniels, Annelise G. Snyder, Tayla M. Olsen, Susana Orozco, Thomas H. Oguin III, Stephen W.G. Tait, Jennifer Martinez, Michael Gale Jr., Yueh-Ming Loo, and Andrew Oberst.

Cell DOI: (10.1016/j.cell.2017.03.011) Copyright © 2017 Elsevier Inc


- Mice lacking RIPK3 are highly susceptible to neuroinvasive West Nile virus
- RIPK3 signaling in WNV-infected neurons results in inflammatory chemokine expression
- WNV-infected, RIPK3-deficient mice display a fatal defect in chemokine-dependent neuroinflammation
- Direct activation of RIPK3 in neurons triggers chemokine production but not cell death


Receptor-interacting protein kinase-3 (RIPK3) is an activator of necroptotic cell death, but recent work has implicated additional roles for RIPK3 in inflammatory signaling independent of cell death. However, while necroptosis has been shown to contribute to antiviral immunity, death-independent roles for RIPK3 in host defense have not been demonstrated. Using a mouse model of West Nile virus (WNV) encephalitis, we show that RIPK3 restricts WNV pathogenesis independently of cell death. Ripk3−/− mice exhibited enhanced mortality compared to wild-type (WT) controls, while mice lacking the necroptotic effector MLKL, or both MLKL and caspase-8, were unaffected. The enhanced susceptibility of  Ripk3−/− mice arose from suppressed neuronal chemokine expression and decreased central nervous system (CNS) recruitment of T lymphocytes and inflammatory myeloid cells, while peripheral immunity remained intact. These data identify pleiotropic functions for RIPK3 in the restriction of viral pathogenesis and implicate RIPK3 as a key coordinator of immune responses within the CNS.

Read the full Cell article here.